BioCentury | May 24, 2019
Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

...BLA mid-2019 (breast); pivotal Ph II (gastric) Breakthrough (breast); Sakigake (gastric) AstraZeneca plc (LSE:AZ; NYSE:AZN) DS-1647...
...is the oncolytic virus DS-1647, which is in Phase II testing to treat glioblastoma multiforme. DS-1647...
...of 92.3% among 13 patients treated. Daiichi plans to submit an NDA to JPMA for DS-1647...
Items per page:
1 - 1 of 1